Abivax (ABVX) Short-Term Debt repayments (2024 - 2026)
Abivax (ABVX) recorded quarterly Short-Term Debt repayments of -$482347.2 in Q1 2026, down 27.34% quarter-over-quarter from -$378773.8 in Q3 2025, and down 99.37% on a YoY basis from -$76.8 million in Q1 2025.
Abivax (ABVX) Short-Term Debt repayments (2024 - 2026) Analysis & Trends
Abivax's Short-Term Debt repayments history runs 3 years deep, the most recent figure standing at -$482347.2 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 102,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -482,347.21 |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -482,347.21 |
| Mar 31, 2026 | -482,347.21 |
| Sep 30, 2025 | -378,773.85 |
| Sep 30, 2025 | -378,773.85 |
| Jun 30, 2025 | -258,086.81 |
| Jun 30, 2025 | -258,086.81 |
| Mar 31, 2025 | -241,933.42 |
| Mar 31, 2025 | -241,933.42 |
| Sep 30, 2024 | -138,375.66 |
| Sep 30, 2024 | -138,375.66 |
| Jun 30, 2024 | -144,302.94 |
| Jun 30, 2024 | -144,302.94 |
| Mar 31, 2024 | -155,349.73 |
| Mar 31, 2024 | -155,349.73 |